Pure Global
NCT05430828

Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy

Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy
Federico II University·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Hypercholesterolemia
Drug/Device/Intervention
Repatha (evolocumab); Praluent (alirocumab)
Study type
Observational
Intervention type
drug
Sponsor & location
Primary sponsor
Federico II University
Location
Bari,Caserta,Catanzaro,Eboli,Foggia,Milano,Napoli,Pescara,Rivoli, Italy
Timeline & enrollment
Phase
N/A
Start date
Mar 07, 2020
End date
Feb 01, 2022
Enrollment
798 participants
Primary outcome

Description of adherence of treatment with PCSK9 inhibitors in a real-life Italian population.,Description of persistence of treatment with PCSK9 inhibitors in a real-life Italian population.,Description of efficacy of treatment with PCSK9 inhibitors in a real-life Italian population.

Summary

Evaluation of adherence, persistence and efficacy of treatment with PCSK9 inhibitors in a
 real-life Italian population.

ICD-10 classifications
Pure hypercholesterolaemiaLipoprotein deficiencyHyperglycaemia, unspecifiedDisorders of lipoprotein metabolism and other lipidaemiasOther disorders of lipoprotein metabolism
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05430828
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05430828 through Pure Global AI's free database. This phase not specified trial is sponsored by Federico II University and is currently Completed. The study focuses on Hypercholesterolemia. Target enrollment is 798 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.